Category Archives: Policy

An Open Letter to Senator Warren Regarding Xtandi

Dear Senator Warren: You have called repeatedly for the federal government to use regulatory tools available to it to address the high prices charged for drugs. Your attention to this matter is much appreciated! I write with specific reference to … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Leave a comment

Outline of the federal framework for the disposition of inventions

Here is an outline of the federal framework for inventions. I have included links to various documents. Lots more to be said, and the brief account here is more gist than deep summary, but perhaps you find it helpful. Plenty … Continue reading

Posted in Bayh-Dole, Policy, Stanford v Roche | Tagged , , , , | Comments Off on Outline of the federal framework for the disposition of inventions

Undermining Bayh-Dole by relying on it? 1

I feel like Charlie Chaplin in a pie factory. Before I could work through an op/ed by Niels Reimers in the Mercury News last April (2021) that the Bayh-Dole Coalition has dredged up to contest the use of march-in to … Continue reading

Posted in Bayh-Dole, Commons, Policy, Stanford v Roche, Technology Transfer | Tagged , , | Comments Off on Undermining Bayh-Dole by relying on it? 1

Five Steps to Restoring an Effective University IP Practice, Step 5

We have been working through five steps to restore a university’s IP practice to something that. might be modestly effective. Abandon AUTM, which has worked for decades against effective IP policy and practices. Abandon compulsory university ownership claims. You may … Continue reading

Posted in Freedom, Policy, Sponsored Research | Tagged , , | Comments Off on Five Steps to Restoring an Effective University IP Practice, Step 5

Five Steps to Restoring an Effective University IP Practice, Step 4

We are working through five steps to getting a university back to an effective IP practice, a practice aligned with academic values and focused on actual technology transfer. The idea of “technology transfer” is bureaucratic in origin. As a concept … Continue reading

Posted in History, Policy, Sponsored Research | Tagged , , , | Comments Off on Five Steps to Restoring an Effective University IP Practice, Step 4

Five Steps to Restoring an Effective University IP Practice, Step 3

We are working through five steps to restoring your university IP practice to something effective and conscionable. The third step involves a fundamental, but again simple, change in policy. Current IP policy at most universities does not address non-exclusive and … Continue reading

Posted in Freedom, Policy | Tagged , , | Comments Off on Five Steps to Restoring an Effective University IP Practice, Step 3

Five Steps to Restoring an Effective University IP Practice, Steps 1 and 2

Over the past couple of years, I have been involved in projects based in the idea of commons for the exchange of research and diagnostic assets. These projects have been blocked or resisted at each point by organizational technology transfer … Continue reading

Posted in Freedom, Policy | Tagged , , , , | Comments Off on Five Steps to Restoring an Effective University IP Practice, Steps 1 and 2

Latkerstein’s Monster, 2

The monopoly meme argument is that no one would have ever received any cisplatin if not for an exclusive license to motivate a big drug company to “develop” the drug as a product. Left out is the idea that the … Continue reading

Posted in Bayh-Dole, History, Policy | Tagged , , | Comments Off on Latkerstein’s Monster, 2

Latkerstein’s Monster, 1

I ran a Twitter thread on this topic. Here’s more of the same. The Bayh-Dole Coalition describes Bayh-Dole as part of a “delicate balance of the university techtransfer system.” My experience differs. There is no “delicate balance.” Bayh-Dole is a … Continue reading

Posted in Bayh-Dole, History, Policy | Tagged , , , | Comments Off on Latkerstein’s Monster, 1

Why the NIH fuss with Moderna over inventorship doesn’t matter, but does

The New York Times ran a story today that Moderna and the NIH are having a spat over inventorship on a patent application covering aspects of the Moderna mRNA vaccine. The N.I.H. had been in talks with Moderna for more … Continue reading

Posted in Bayh-Dole, Bozonet, Policy | Tagged , , , , | Comments Off on Why the NIH fuss with Moderna over inventorship doesn’t matter, but does